Compare ZYME & AIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | AIN |
|---|---|---|
| Founded | 2003 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Textiles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2022 | 1994 |
| Metric | ZYME | AIN |
|---|---|---|
| Price | $23.40 | $48.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 4 |
| Target Price | $38.90 | ★ $60.25 |
| AVG Volume (30 Days) | ★ 649.0K | 279.3K |
| Earning Date | 03-02-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | ★ 33.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $105,965,000.00 | ★ $1,054,132,000.00 |
| Revenue This Year | $162.82 | $1.20 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 38.87 | 7.29 |
| 52 Week Low | $9.03 | $41.15 |
| 52 Week High | $28.49 | $74.16 |
| Indicator | ZYME | AIN |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 26.76 |
| Support Level | $22.28 | $41.15 |
| Resistance Level | $23.66 | $60.43 |
| Average True Range (ATR) | 1.36 | 1.70 |
| MACD | -0.08 | -0.87 |
| Stochastic Oscillator | 16.70 | 1.33 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.